Page 39 - Cell Line News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr. Katie Sagrero became concerned several weeks ago when upset patients began calling her South Omaha clinic with questions about a flyer in Spanish that suggested the two vaccines approved for COVID-19 contained tissue from aborted fetuses. To provide some answers, Sagrero, a family physician with OneWorld Community Health Centers, revived the video series she had been doing for the Spanish news station Radio Lobo. Neither the Pfizer nor Moderna vaccines contain aborted fetal cells, Sagrero explained in the Spanish-language video now available on YouTube. In addition, the Catholic Church ha...

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is thought to be a disease originally occurring in animals but transmitted across the species barrier to human beings, probably through an intermediate host. Following human infection, the virus has been shown to transmit to some pet and farm animals, where it then mutates. A new preprint research paper posted to the bioRxiv* server shows that these mutations disrupt inhibition by neutralizing ant...

Scientists conduct interdisciplinary study on using nanoparticles to fight leukemia Scientists from Scientific and Educational Center & Smart Materials and Biomedical Applications under the leadership of Kateryna Levada together with colleagues from Center for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University conducted a joint interdisciplinary study on the development of a new method for treating leukemia using nanomaterials. The scientists analyzed how magnetic nanoparticles can be manipulated in in vitro conditions to achieve a selective antitumor effect....

Hybridomas Segment to Register Highest CAGR in Cell Line Development Market during 2020-2027 The market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027 The global cell line development market, based on type, is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest share of the market in 2019. This growth is ascribed to the increasing demand for recombinant cell lines in the production of t...

Fetal Bovine Serum Segment to Grow at Fast Pace during 2020-2027. The market is expected to reach US$ 1,467.92 million by 2027 from US$ 915.58 million in 2019; it is estimated to grow at a CAGR of 6.1% from 2020 to 2027. The report provides trends prevailing in the global cell line development serum market, and the drivers and hindrances pertaining to the market growth. Based on type, the global cell line development serum market is segmented into fetal bovine serum, adult bovine serum, porcine serum, horse serum, other animal serum. Fetal bovine serum segment held the largest share of the m...